 SUZHOU and SHANGHAI, China, April 10, 2021 PRNewswire -- Gracell Biotechnologies Inc. NASDAQ: GRCL Gracell, a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today presented updated long-term follow-up data on their TruUCAR-enabled allogeneic product candidate GC027 for the treatment of adult patients with relapsedrefractory T-cell acute lymphoblastic leukemia rr T-ALL in an e-poster presentation at the 2021 American Association for Cancer Research AACR Annual Meeting on April 10. TruUCAR-enabled GC027 is a first-in-human, off-the-shelf allogeneic CAR-T stand-alone therapy targeting CD7. 